These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24248806)

  • 1. Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients.
    Mohamed S; Ravet S; Camus C; Khiri H; Olive D; Halfon P
    J Med Virol; 2014 Mar; 86(3):394-403. PubMed ID: 24248806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
    Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
    Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure.
    Mohamed S; Penaranda G; Gonzalez D; Camus C; Khiri H; Boulmé R; Sayada C; Philibert P; Olive D; Halfon P
    AIDS; 2014 Jun; 28(9):1315-24. PubMed ID: 24698843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
    Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
    Van Eygen V; Thys K; Van Hove C; Rimsky LT; De Meyer S; Aerssens J; Picchio G; Vingerhoets J
    J Med Virol; 2016 May; 88(5):798-806. PubMed ID: 26412111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing.
    García-González C; García-Bujalance S; Ruiz-Carrascoso G; Arribas JR; González-García J; Bernardino JI; Pascual-Pareja JF; Martínez-Prats L; Delgado R; Mingorance J
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):90-6. PubMed ID: 22078905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
    Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
    J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.
    Balduin M; Oette M; Däumer MP; Hoffmann D; Pfister HJ; Kaiser R
    J Clin Virol; 2009 May; 45(1):34-8. PubMed ID: 19375978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
    Pereira-Vaz J; Duque V; Pereira B; Mota V; Morais C; Saraiva-da-Cunha J; Meliço-Silvestre A
    J Med Virol; 2012 Apr; 84(4):551-4. PubMed ID: 22337292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
    Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
    Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.